INSIGHTS

Insights that cut through complexity

Q3 2021 Drug Pipeline Recap

Q3 2021 Drug Pipeline Recap

The Latest Developments in Drug Approvals Each quarter, the RemedyOne Clinical team curates a drug pipeline report for our clients…
No One Really Knows How We’ll Pay for Gene Therapies

No One Really Knows How We’ll Pay for Gene Therapies

Gene therapies are here and they have the potential to be miraculous. And extremely expensive. The science behind these therapies…
COVID-19 Treatment Update

COVID-19 Treatment Update

The last year and a half brought many rapid changes and innovations across the globe and in no area more than healthcare. From finding the most effective treatments to developing tests and…
The Implications of Polypharmacy on the Payor and Patient

The Implications of Polypharmacy on the Payor and Patient

There is a delicate balance between prescribing new medications and identifying and eliminating unnecessary prescriptions to protect the overall care…
2021 Q3 RemedyOne Quarterly Pipeline Report

2021 Q3 RemedyOne Quarterly Pipeline Report

Download our 2021 Q3  Quarterly Drug Pipeline Report Our quarterly pipeline report provides insight into specialty and traditional drugs in…
Biogen’s New Alzheimer’s Drug is a Compound of Hope and Controversy

Biogen’s New Alzheimer’s Drug is a Compound of Hope and Controversy

For the first time in 18 years, the FDA has approved a drug to treat patients with Alzheimer’s disease. It’s…
Like what you’re seeing? Get more Insights sent to you.
  • This field is for validation purposes and should be left unchanged.